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requires global collaboration and concerted effort to share creative
ideas, pool talents and develop sustainable support from govern-
ments, industry, academia and non-governmental organizations.
Comprehensive cancer care, which fits within and strengthens
the broader healthcare system, ranges from prevention to screen-
ing, to curative treatment, to palliative care and to long-term fol-
low-up. Radiation therapy is an essential component for curative
and palliative cancer care and can serve as a stable focal point
physically and for personnel around which regional cancer and
health care programs can be established. To build capacity with
high quality capability and with the credibility to conduct research
to understand specific diseases and treatment outcomes requires a
complex systems approach toward both expertise and technology.
To move forward in the aspirational goal of substantially reduc-
ing the global burden of cancer as part of the Sustainable Develop-
ment Goals of the United Nations [1], a workshop was convened
on November 7–8, 2016 by the International Cancer Expert Corps
(ICEC) [2] and hosted by CERN [3]. Entitled ‘‘Design Characteristicsand Implementation of a Novel Linear Accelerator for Challenging
Environments” a major focus was on innovative radiation oncology
technology opportunities. Cobalt-60 units are still in use but, while
newer units are increasingly sophisticated, they do not provide the
full treatment capability ofmodern linacs and require ongoing secu-
rity and ever-increasing costs for disposal of radioactive materials.
While there has been substantial progress in radiation oncology
technology development, significant opportunity remains for
improvement and innovation in the combination of technology
and processes used to deliver basic and advanced radiation therapy
in low- and middle-income countries. Most specifically, the
adoption of a collaborative approach that ties together broad
expertise and perspectives by connecting global need, oncology
expertise, and deep capacity in technology innovation was
reinforced by this workshop and subsequent efforts and has
resulted in a framework for collaboration to address the
unacceptable gap in global cancer care.The magnitude of the problem
It is estimated that the annual global cancer incidence will rise
from 15 million cases in 2015 to as many as 25 million cases in
2035, 65–70% of which will occur in low- and middle-income
countries (LMICs) [4] where there is a severe shortfall in radiation
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ogy, imaging, the range of oncology expertise, nursing and support
staff, with at least 50% of cancer patients benefiting from radio-
therapy regardless of their geographic location [5]. Radiotherapy
is an effective curative and palliative modality for a very broad
range of tumors. Yap, et al. have estimated that, if the demand
for radiotherapy is met in LMICs by 2035, each year an additional
1.3 million people would experience local disease control and over
615,000 patients would derive a survival benefit [6] with other
estimates closer to 1 million per year [7–9]. For the advanced
stages of cancer for which surgery is not feasible, radiotherapy
can still be curative. Without radiotherapy, effective palliative care
is often absent and particularly so in countries that limit the use of
narcotics. When considering investment in overall global health-
care, the relationship between the etiology and management of
the non-communicable diseases – cardiovascular, metabolic, respi-
ratory, and oncologic – and the communicable diseases, particu-
larly those for which screening and prevention are available (e.g.,
HPV related illness and hepatitis), gives cancer care an opportunity
to be the focal point for coordination, collaboration and strength-
ening health systems networks.
A Lancet Oncology Commission, the Global Task Force on Radio-
therapy for Cancer Control (GTFRCC) of the Union for International
Cancer Control (UICC) [7], supported by additional recent data [10],
documented the global demand for radiotherapy, the resources
required and the economic and societal benefits that would be
reaped by additional investment in providing such coverage. It
was estimated that as many as 12,600 megavoltage treatment
machines will be needed to meet the radiotherapy demands in
LMICs by 2035. Using current staffing models, there will be an esti-
mated need by that time for an additional 30,000 radiation oncol-
ogists, more than 22,000 medical physicists and almost 80,000
radiation technologists. The financial investment needed in LMICs
is approaching $200B USD and the economic benefits demonstrate
significant returns to those countries that choose to invest.
Workshop participants from global health, cancer care, and
radiation technology fields addressed: (1) the role of radiotherapy
in treating patients with cancer in the challenging environments of
many LMICs, (2) the security concerns related to high-activity radi-
ological sources in medical facilities, (3) the design characteristics
of linear accelerators and related technologies for use in challeng-
ing environments, (4) the education, training and mentoring of the
sustainable workforce needed to utilize novel radiation treatment
systems and (5) the costs and financing of the implementation of
the recommendations from the workshop.
The workshop agenda can be found online [9]. Issues raised
there and at subsequent discussions during the International Con-
ference on Advances in Radiation Oncology (ICARO2) [12] in June,
2017 and at a second workshop held at CERN on October 26 and
27, 2017 showed clear evidence that technological opportunities
exist to improve global access to radiation treatment.
Focusing on the machine alone will not solve the problem
Numerous national scientific societies and non-governmental
organizations (NGOs) provide training globally on a limited scale
for radiotherapy professionals and allied health personnel. Radiat-
ing Hope, a US-based NGO, provides radiotherapy equipment, often
refurbished, on a limited scale to regions that have limited or no
capacity [13]. Successful approaches to peer-supported case-based
education including pioneering work by Hardenburgh via Char-
trounds [14] and the potential for use of highly interactive telecon-
ferencing, such as TELESYNERGY, developed by the National
Institutes of Health for cancer disparities programs [15], are con-
sidered critical to education and mentorship. By far, the greatest
body of effort and experience in developing radiation treatmentcapacity in LMICs resides with the International Atomic Energy
Agency (IAEA). The aim of IAEA’s program on Human Health
(NAHU) [16] is to enhance the capabilities in Member States to
address needs related to the prevention, diagnosis and treatment
of diseases through the application of nuclear techniques. Their
Human Health Campus [17] website posts extensive and detailed
guidelines for the implementation of radiotherapy programs as
well as education and training syllabi and course materials for
the diverse professions involved in delivering radiotherapy.
Through the IAEA Technical Cooperation Programme, including
its Program of Action for Cancer Therapy (PACT) [18], the IAEA
addresses the needs of IAEA LMIC Member States by supporting
the implementation of radiotherapy programs and by expanding
their efforts through cooperation with non-governmental donors.
Successful instances in which an optimal mix of local commit-
ments was available were presented at the workshop [11] as
examples of radiotherapy programs that have thrived and are
expanding. On the other hand, the lack of secure resources, inade-
quate planning, the failure of local governments to keep commit-
ments and political instability resulted in weak programs and
lack of continuity. Among the current IAEA criteria for project sup-
port are: (1) political stability in the country or region, (2) local
commitment and (3) political will for sustained ownership and
long-term funding of the program. A typical project includes a
medium-term plan for the establishment of the first radiotherapy
department in a region and a long-term plan that includes ade-
quate staffing and creation of a local training program that will
allow the facility to become a nucleus for future regional expan-
sion. Successful regional training centers are stabilizing factors that
can mitigate the so-called ‘‘brain drain” pressures.
Among the major points of the discussions [11] were:
1. The importance of local champions [19] and local and regional
investment in resources. Top-down solutions from upper-
income countries contain useful tools and frameworks but the
needs, solutions and time-tables should be driven by specialists
in local communities and external experts who best understand
the issues. Examples of guidelines being developed for LMICs
that can be a useful starting point for program building are
the National Comprehensive Cancer Network (NCCN) Harmo-
nized Guidelines for Sub-Saharan Africa [20]. Purchase or dona-
tion of equipment to countries in which there is inadequate
infrastructure and technical capability can result in money
wasted or in technology not used appropriately and/or
effectively.
2. The treatment capability must not be considered ‘‘second-rate”
but should be on par with that generally available for cancer
care in developed nations. (The highly innovative and expensive
technologies, such as particle therapy, should be considered on
a regional level, with appropriateness for treatment based on
carefully defined criteria.)
3. Research is a key part of this overall enterprise including: (a)
population studies to define the cancer problem locally or
regionally, (b) biology and epidemiology investigations to
understand how genes, environment, the microbiome and
infectious agents impact cancer, (c) cancer treatment outcomes
studies, (d) policy projects for access to healthcare including
access to multiple specialists and supportive care and (e) eco-
nomic analyses for balancing cost and resources and guiding
future investment.
4. Technical programs that might bear on the development of a
novel linear accelerator and treatment system are ongoing
[11]. Subsequent meetings have addressed specifics of the lin-
ear accelerator design and implementation, including a
‘‘BOXCare” concept proposed by Jaffray [21].
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therapy has utility and is recognized by its use in LMICs, includ-
ing the relative roles of linac versus cobalt-60, was recently
reviewed (and not a topic of this workshop) [22]. The Office of
Radiological Security (ORS) of the United States National
Nuclear Security Administration (NNSA) [23] stressed the risk
posed by malicious use of high-activity radiological sources,
and the potential for linacs to permanently reduce these radio-
logical security risks by providing high-quality treatment with-
out the use of cobalt-60. For hospitals that utilize cobalt-60
teletherapy machines, ORS emphasized the need to protect
the radioactive sources from unauthorized access. This theme
was expanded by a report from the Center for Nonproliferation
Studies (CNS) [24] in the new paradigm ‘‘Treatment, not Terror”
[25,26].
6. There is novel technology being developed at Stanford and the
SLAC National Accelerator Laboratory at Stanford University
that is a pluri-directional high energy agile scanning electronic
radiotherapy system (PHASER) using advanced RF linac tech-
nology that employs 16 independent electron beams. The
device is capable of delivering a radiation dose approximately
300 faster than a conventional medical linear accelerator.
While an interesting concept, the potential role for this technol-
ogy in resource-rich and lower-middle income countries will
depend on future development and costs of both equipment
and power.
7. An ideal radiotherapy treatment system characteristic is modu-
larity in order to make it easy to ship, to assemble in-situ, to
repair and to upgrade periodically as local patient treatment
expertise develops. Policies and procedures must be developedFig. 1. Building global cancer care: capacity, capability, credibility and continuity. See tex
Européen pour la Recherche Nucléaire, or European Organization for Nuclear Research; IA
– Union Internationale Contre le Cancer or Union for International Cancer Control; NASA
National Nuclear Security Administration. Graphic by David Herbick.to minimize the need for local specialized technical staff to
maintain the equipment and promptly repair it. In addition, a
national or regional supply of standard (modular) spare parts
and uncomplicated replacement procedures will be needed in
order to make maintenance reliable and easy.
Moving ahead
The medium-term goal for technology development is to ‘bury
the complexity’ [27] of radiotherapy by taking advantage of
software to incorporate automation to affect ease of use and, in
conjunction with excellent diagnostic imaging, to insure high
quality treatment. In addition, examples of the emerging role of
software to lower the cost of radiotherapy through new software
tools (optimization and automation) demonstrated that software
can compensate for machine ‘‘weakness” and can eliminate
inconsistencies in simulation and treatment planning [28].
That the solution for global cancer care requires attention to
expertise and technology and is an opportunity for global leader-
ship by radiation and clinical oncologists is illustrated in Fig. 1.
The focus is on patient care based on healthcare systems in LMIC
centers. Onsite expertise is essential and robust technology is crit-
ical for sustainable programs. The specific expertise and criteria for
the technology are noted within the figure. The unique aspects of
the implementation model include global mentoring and expert
support. These provide mentoring for the onsite experts and the
creative global technology partners and collaborators to support
and enhance the existing technology and to develop innovative
solutions. This is not a theoretical construct since there are ongoingt for details. Abbreviations: ICEC – International Cancer Expert Corps: CERN – Conseil
EA – International Atomic Energy Agency; WHO –World Health Organization; UICC
– National Aeronautics and Space Administration; NNSA – Department of Energy,
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and as part of recent issues on global health [29–31].
A presentation on entrepreneurial strategies highlighted how
disruptive innovation [32] requires cooperation across disciplines.
ICEC’s unique strategy is to establish a sustainable team of mentors
to guide local cancer care providers throughout the various phases
of training and implementing guideline- or protocol- based cancer
control and treatment programs [33,34]. In this way, each cancer
disparities region radiation treatment center would be aligned
with mentors based in a university cancer center or private
practice radiotherapy center in a resource-rich country. After
centers in low-resource regions develop sufficient expertise and
meet global guideline- and/or protocol-based standards for cancer
care, they can become regional resource centers for less developed
local groups that are motivated to undertake a similar path.
Professionals in medical oncology, radiation oncology, surgery,
medical physics as well as nurses and ancillary staff will be
recruited in order to ensure mentoring of all of the members of
the treatment teams in LMICs. Implementing these programs will
require sustainable support, a career path for mentors [35],
multi-sector involvement to take advantage of the broad favorable
impact cancer care will have [36] and visionary leadership from
NGOs, industry, government and international health and global
security-related agencies.
Actions
Three tasks forces are at work.Task Force 1: Technical Task Force
From a systems perspective stimulate innovation in radiother-
apy technologies and processes. In the near-term, develop optimal
design requirements for a novel high-quality, lower-cost treatment
solution that leverages existing linac technologies and incorporates
intelligent software designed for robust operation in a range of
challenging environments. Such a system would be modular,
rugged, easily operated, less reliant on personnel, and easily
repaired but sufficiently sophisticated to also bring benefits to
radiotherapy in high-income countries. This is an example of
reverse innovation with learning passing from low- to high-income
countries [37,38].
For the long-term, clearly identify shortfalls in existing criti-
cal subsystems (radiation production, power consumption, heat
dissipation, automated maintenance, electromechanical collima-
tion, imaging, safety, and training subsystems) and, through
engagement of international centers of excellence, stimulate
the development of next generation solutions to these impor-
tant needs.Task Force 2: Education, Training and Mentoring Task Force
Identify (a) the education and training requirements for cur-
rent as well as future radiotherapy equipment and treatment
systems worldwide, (b) the current extent of education and
training program resources and (c) the education and training
needed to fill the gaps. In coordination with Task Force 1,
develop recommendations for specific training and mentoring,
including new education technology, to ensure that the advanced
radiotherapy treatment systems will be fully utilized as soon as
they are introduced in the near-term as well as in the more dis-
tant future. Continuously evaluate the impact of changing pat-
terns of practice and treatment techniques, and changes in
cancer incidence and population mix in order to appropriately
update content and methodology of education, training and
mentoring programs.Task Force 3: Global Connectivity and Development Task Force
Linked closely with Task Forces 1 and 2, develop and implement
a strategy for securing financial support in client countries as well
as from governmental, academic and philanthropic organizations
and individuals to insure success of the effort to make excellent
near-term and long-term radiation treatment systems, including
staffing and physical infrastructure, available for the treatment of
patients with cancer in LMICs and other geographically under-
served regions worldwide. Patient engagement as seen in the can-
cer survivorship community is critical to optimal design on cancer
care systems [39].
Summary and conclusion
The magnitude of the global shortfall in cancer care, especially
radiation oncology, is a crisis that cannot be ignored and presents
an opportunity for innovative systems solutions to include devel-
opments in technology, capacity, expertise, advanced treatment
capability and sustainable mentorship and education. Detailed def-
inition and documentation of the problem provides essential met-
rics upon which to make improvements, but action is required to
begin to implement solutions to the urgent need for expertise
and enabling technology. This initial workshop and subsequent
progress are important steps toward solutions. Indeed, this is an
example where reverse innovation and disruptive technology can
transform cancer care in the underserved world for the better
while reducing costs and bringing innovative science and technol-
ogy to the better-resourced world. The potential of this effort to
have a positive impact on the lives of millions of people presents
a great opportunity for global collaboration, sustainable cross-cul-
tural relationships and a leadership role for healthcare to create
common bonds among nations.
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